This compound, 2,3-dinor-11β-Prostaglandin F2α, is the major urinary metabolite of 11β-PGF2α, a prominent F2-isoprostane formed via non-enzymatic lipid peroxidation. It is primarily utilized in medical and biochemical research as a validated biomarker to quantify in vivo oxidative stress and assess levels of systemic lipid peroxidation. Researchers employ it to investigate the implications of oxidative stress in inflammation, cardiovascular diseases (such as atherosclerosis and hypertension), pulmonary conditions, and other pathologies linked to reactive oxygen species. Additionally, it supports the evaluation of antioxidant therapies and the efficacy of interventions targeting oxidative damage, contributing to the development of diagnostics and treatments for oxidative stress-related disorders.